Project documents | Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261] | Guidance | NICE

Documents

A list of downloadable documents created during development.

Final draft guidance: 2

Final draft guidance: 2
Final draft guidance ^{PDF 522 KB} 09 April 2024
Committee papers ^{PDF 2.47 MB} 09 April 2024
Public committee slides ^{PDF 520 KB} 09 April 2024
Equality impact assessment ^{PDF 163 KB} 09 April 2024

Draft guidance: 2

Draft guidance: 2
Appraisal consultation document (PDF version) ^{PDF 495 KB} 18 January 2024
Appraisal consultation document (online commenting)
Committee papers ^{PDF 4.37 MB} 18 January 2024
Public committee slides ^{PDF 1.97 MB} 18 January 2024
Draft guidance (PDF version) - Equality impact assessment ^{PDF 149 KB} 18 January 2024

Consultation documents published: Consultation on the in vitro data on neutralising monoclonal antibodies for COVID-19: methods framework

Appeal

Appeal
AstraZeneca : Appeal letter ^{MSWord 43 KB} 02 May 2023
Gilead : Appeal letter ^{MSWord 188 KB} 02 May 2023
Merck Sharp & Dohme : Appeal letter ^{PDF 2.01 MB} 02 May 2023
Gilead : Scrutiny letter ^{MSWord 93 KB} 02 May 2023
Merck Sharp & Dohme : Scrutiny letter ^{MSWord 87 KB} 02 May 2023
Gilead : Response to scrutiny letter ^{MSWord 147 KB} 02 May 2023
Merck Sharp & Dohme : Response to scrutiny letter ^{PDF 293 KB} 02 May 2023
Gilead : Final scrutiny letter ^{MSWord 64 KB} 02 May 2023
Merck Sharp & Dohme : Final scrutiny letter ^{MSWord 70 KB} 02 May 2023
Appeal decision ^{PDF 773 KB} 05 July 2023

Final draft guidance

Final draft guidance
Final appraisal document ^{PDF 518 KB} 21 February 2023
Committee papers ^{PDF 10.21 MB} 21 February 2023
Public committee slides ^{PDF 1.95 MB} 21 February 2023
Public committee slides - in vitro presentation ^{PDF 8.57 MB} 21 February 2023

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) ^{PDF 391 KB} 16 November 2022
Appraisal consultation document (online commenting)
Committee papers ^{PDF 15.32 MB} 16 November 2022
Public committee slides ^{PDF 2.48 MB} 16 November 2022

Invitation to participate

Final scope ^{PDF 249 KB} 01 August 2022
Final stakeholder list ^{PDF 174 KB} 01 August 2022
NICE's response to comments on the draft scope and provisional stakeholder list ^{PDF 1.35 MB} 01 August 2022
Equality impact assessment (Scoping) ^{PDF 137 KB} 01 August 2022
Statement from NICE and the SMC/HIS ^{PDF 93 KB} 28 September 2022

Assessment report sent for information

Assessment report ^{PDF 1.17 MB} 11 July 2022

Invitation to participate

Final scope ^{PDF 246 KB} 19 April 2022
Provisional Stakeholder List (post-referral) ^{PDF 172 KB} 19 April 2022
Final protocol ^{PDF 384 KB} 19 April 2022
Supporting documentation - Stakeholder Information Meeting slides ^{PDF 212 KB} 19 April 2022
Supporting documentation - Process statement ^{PDF 163 KB} 28 September 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope pre referral ^{PDF 251 KB} 14 January 2022
Draft matrix post referral ^{PDF 187 KB} 02 February 2022